Diamyd Medical today announced that the screening period in its pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals with type 1 diabetes has been completed. Based on the nu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback